A cancer registry collects and combines detailed information about cancer patients and the initial treatments they receive to answer questions like—
Is there a certain area of a state where women are finding out they have breast cancer at a late stage, when it’s harder to treat?
Where will prevention efforts, like screening, have the biggest benefit?
What groups of people are most likely to get a certain type of cancer, like liver or skin cancer?
Cancer registries analyse the data collected and share the answers to these questions with other groups, like state comprehensive cancer control coalitions, which work to prevent cancer. These groups may find that some people aren’t getting cancer screening tests, or they’re making choices that raise their chance of getting cancer. The data may also show that certain groups of people are getting cancer more than others.
Cancer control groups and advocates work to address the problems identified. Then they look to cancer registries for new information to help them know if their solutions are working.
OPINIONI found some of the quotes from the recent NET SEER Database study (Dasari et al) very interesting. The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program is a comprehensive source of population-based information initiated in 1973 that is updated annually. Although the study is US-based, it represents the largest study of Neuroendocrine Neoplasms (NENs) ever recorded and is therefore a good guide to what might be found beyond USA. Almost 7 times the rate recorded in the 1970s. If you want to understand the factors behind this massive increase, I covered this extensively in my post "Neuroendocrine Neoplasms – not as rare as you think". However, most things I read indicate the figures were understated (words used by several NET specialists. Despite this date now being 8 years…